A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)

NCT01010906 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Vaniprevir 300 mg
DRUG: Vaniprevir 200 mg

Sponsor

Merck Sharp & Dohme LLC